Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
Saturday 29 January 2022 11:31 am  |  Updated:  Saturday 29 January 2022 11:42 am

Coronavirus close-up: Long Covid changes some patients’ lungs forever

By: Michiel Willems

Add as a preferred source on Google
medicines on a red surface
Photo by Maksim Goncharenok on Pexels.com

Many long Covid patients who have breathlessness experience abnormalities in the lungs of long which cannot be detected with routine tests.

In fact, there is significantly impaired gas transfer from the lungs to the bloodstream in the long Covid patients despite other tests – including CT scans – coming back as normal, according to a new study out this weekend.

The Explain study used xenon, an odourless, colourless, tasteless and chemically non-reactive gas, to investigate possible lung damage in the patients who have not been admitted to hospital, but continue to experience the symptom.

The study’s chief investigator, Fergus Gleeson, professor of radiology at the University of Oxford and consultant radiologist at Oxford University Hospitals NHS Foundation Trust, said: “We knew from our post-hospital Covid study that xenon could detect abnormalities when the CT scan and other lung function tests are normal.

“What we’ve found now is that, even though their CT scans are normal, the xenon MRI scans have detected similar abnormalities in patients with long Covid.”

“These patients have never been in hospital and did not have an acute severe illness when they had their Covid-19 infection.”

Fergus Gleeson, professor of radiology at the University of Oxford

“Some of them have been experiencing their symptoms for a year after contracting Covid-19.

“There are now important questions to answer. Such as, how many patients with long Covid will have abnormal scans, the significance of the abnormality we’ve detected, the cause of the abnormality, and its longer-term consequences.

“Once we understand the mechanisms driving these symptoms, we will be better placed to develop more effective treatments.”

Long Covid

In the study, the patients were required to lie in an MRI scanner and breathe in one litre of the gas that has been tweaked so that it can be seen using MRI.

Because xenon, which is safe to inhale, behaves in a very similar way to oxygen, radiologists can observe how it moves from the lungs into the bloodstream.

The scan takes just a few minutes and, as it does not require radiation exposure, can be repeated over time to see changes to the lungs.

Read more

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

While the full Explain study will recruit about 400 participants, the initial pilot had 36 participants making up three groups.

This included those diagnosed with long Covid who had been to long Covid clinics and who had normal CT scans, and people who had been in hospital with coronavirus and discharged more than three months ago, who had normal or nearly normal CT scans and who were not experiencing long Covid.

The third group was an age and gender-matched control group who did not have long Covid symptoms and were not admitted to hospital with the virus.

Structural changes to the lungs

Dr Emily Fraser, respiratory consultant who leads the Oxford Post-Covid Assessment Clinic, said: “These are interesting results and may indicate that the changes observed within the lungs of some patients with long Covid contribute to breathlessness.

“However, these are early findings and further work to understand the clinical significance is key.”

Asked what people suffering from the symptom can take from the findings, she added: “I think that the message should be that we are actively researching what is driving long Covid.”

But Dr Fraser also said people should not give up on the current exercises and rehab they are working on, as this is also helpful.

The method and clinical applications were developed by Professor Jim Wild and the Pulmonary, Lung and Respiratory Imaging Sheffield (Polaris) research group at the University of Sheffield.

Prof Wild said: “Xenon follows the pathway of oxygen when it is taken up by the lungs and can tell us where the abnormality lies between the airways, gas exchange membranes and capillaries in the lungs.”

The study, which received Government funding, is supported by the NIHR Oxford Biomedical Research Centre (BRC).

The findings, which have not been peer-reviewed, were posted on the bioRxiv pre-print server.

Read more

cTAP Announces Novel Prognostic Score Developed for Duchenne Muscular Dystrophy Patients Offers Improved Prediction of Loss of Ambulation

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus

Trending Articles

  • Burnham told to launch £100bn tax reform package

  • Billionaire Easyjet founder in line for £800m payday from takeover

  • Construction sector cuts jobs again as house building slumps

  • Harry Styles at Wembley Stadium review: running through the grief

  • Tickets for England World Cup quarter vs Norway on sale for $8m

More from City PM

  • Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

    Business Wire
  • cTAP Announces Novel Prognostic Score Developed for Duchenne Muscular Dystrophy Patients Offers Improved Prediction of Loss of Ambulation

    Business Wire
  • Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

    Business Wire
  • LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

    Business Wire
  • Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

    Business Wire
  • Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

    Business Wire
  • LivaNova Appoints Anne Liddy as Chief Legal Officer

    Business Wire
  • Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy